Serum IL-31 levels are increased in patients with cutaneous T-cell lymphoma

Acta Dermato-Venereologica

Volumn 92, Issue 3, 2012, Pages 282-283

  Ohmatsu, Hanako ^a   Sugaya, Makoto ^a   Suga, Hiraku ^a   Morimura, Sohshi ^a   Miyagaki, Tomomitsu ^a   Kai, Hiromichi ^a   Kagami, Shinji ^a   Fujita, Hideki ^a   Asano, Yoshihide ^a   Tada, Yayoi ^a   Kadono, Takafumi ^a   Sato, Shinichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 31;

ADULT; CANCER STAGING; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; ERYTHRODERMA; FEMALE; HUMAN; LETTER; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SKIN DEFECT; TUMOR;

ADULT; AGED; DERMATITIS, ATOPIC; HUMANS; INTERLEUKINS; MIDDLE AGED; MYCOSIS FUNGOIDES; NEOPLASM STAGING; SEVERITY OF ILLNESS INDEX; SEZARY SYNDROME; SKIN NEOPLASMS; YOUNG ADULT;

EID: 84859741123     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-1345     Document Type: Letter

References (12)

1. Dillon SR, Sprecher C, Hammond A, Bilsborough J, Rosenfeld-Franklin M, Presnell SR, et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol 2004; 5: 752-760.
2. Takaoka A, Arai I, Sugimoto M, Yamaguchi A, Tanaka M, Nakaike S. Expression of IL-31 gene transcripts in NC/ Nga mice with atopic dermatitis. Eur J Pharmacol 2005; 516: 180-181.
3. Sonkoly E, Muller A, Lauerma AI, Pivarcsi A, Soto H, Kemeny L, et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 2006; 117: 411-417.
4. Raap U, Wichmann K, Bruder M, Stander S, Wedi B, Kapp A, et al. Correlation of IL-31 serum levels with severity of atopic dermatitis. J Allergy Clin Immunol 2008; 122: 421-423.
5. Kakinuma T, Sugaya M, Nakamura K, Kaneko F, Wakugawa M, Matsushima K, et al. Thymus and activation-regulated chemokine (TARC/CCL17) in mycosis fungoides: serum TARC levels reflect the disease activity of mycosis fungoides. J Am Acad Dermatol 2003; 48: 23-30.
6. Miyagaki T, Sugaya M, Fujita H, Ohmatsu H, Kakinuma T, Kadono T, et al. Eotaxins and CCR3 interaction regulates the Th2 environment of cutaneous T-cell lymphoma. J Invest Dermatol 2010; 130: 2304-2311.
7. Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 1713-1722.
8. Marti RM, Estrach T, Reverter JC, Mascaro JM. Prognostic clinicopathologic factors in cutaneous T-cell lymphoma. Arch Dermatol 1991; 127: 1511-1516.
9. Hassel JC, Meier R, Joller-Jemelka H, Burg G, Dummer R. Serological immunomarkers in cutaneous T cell lymphoma. Dermatology 2004; 209: 296-300.
10. Yagi Y, Andoh A, Nishida A, Shioya M, Nishimura T, Hashimoto T, et al. Interleukin-31 stimulates production of inflammatory mediators from human colonic subepithelial myofibroblasts. Int J Mol Med 2007; 19: 941-946.
11. Sugaya M. Chemokines and cutaneous lymphoma. J Dermatol Sci 2010; 59: 81-85.
12. Demierre MF, Gan S, Jones J, Miller DR. Significant impact of cutaneous T-cell lymphoma on patients' quality of life: results of a 2005 National Cutaneous Lymphoma Foundation Survey. Cancer 2006; 107: 2504-2511.